|
Published by: SMI Publishing, Ltd
Published: Jun. 6, 2007
Table of Contents
- Day One
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Ramkrishna Sadhukhan, Senior Research Scientist, Bioresearch Centre, Abbott Laboratories.
- 9.10 NOVEL APPROACHES FOR EFFICIENT PROTEIN PRODUCTION IN DRUG DISCOVERY
- The impact of a standardized and still flexible process in protein expression and purification
- Versatile set of vectors for multi-parallel expression in different host cells experimenting with novel technologies through outsourcing of lead discovery and early research
- Streamlined procedure for a quick determination of expression levels in small culture volumes
- Automated multi-step chromatography allowing a fast recovery of purified protein in high yields
- Dr Lukas Leder, Research Investigator, Protein Expression and Purification, Centre of Proteomic Chemistry, Novartis.
- 9.50 PURIFIED MEMBRANE PROTEIN IN DRUG DISCOVERY
- Expression, purification, structural analysis and biophysical characterization of GPCRs and ICs
- Production of mg quantities of membrane protein targets for drug discovery
- Exploitation of these reagents for crystallography and biophysical mode of action analysis
- Opportunities for biologics
- Dr Niek Dekker, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca.
- 10.30 Morning Coffee
- 10.50 ASSESSING THE COSTS AND REWARDS OF DIFFERENT EXPRESSION SYSTEMS FOR PROTEIN STRUCTURAL WORK
- Comparative analysis of success rates for hard-to-express proteins
- Analyzing the transition to higher-level expression systems based on accumulated data
- Valuing the possibilities of further expanding to mammalian cell expression systems
- Dr Robert Wynands, Director, Structural Biology, Takeda .
- 11.30 INCREASING PROTEIN STABILITY DURING RECOMBINANT PROTEIN PRODUCTION
- Enhancing protein stability using carbohydrate polymers
- Stabilisation of proteins at 4°C or over several freeze/thaw cycles
- Maintaining the stability of fusion proteins after tag is removed
- Increasing the concentration of difficult to handle proteins
- Improving purification procedures by increasing the yield and quality of protein obtained
- Dr Sheena Whyte, Project Leader, Novexin.
- 12.10 Networking Lunch
- 1.20 STREAMLINING EXPRESSION SCREENING IN BACULOVIRUS EXPRESSION SYSTEMS
- The impact on protein research
- Eliminating bottlenecks in production of eukaryotic proteins
- Multi-paralleled expression screening in baculovirus expression systems
- Automation of baculovirus expression screening
- Small scale Expression analysis vs. scale-up results
- Dr Alycia Shoultz, Scientist, Biologics and Biomolecular Sciences, Boehringer Ingelheim.
- 2.00 COMPUTER AIDED MULTI-PARAMETER GENE DESIGN
- Impact of Synthetic DNAs on Protein Expression Enhancement
- Prof Ralf Wagner, Chief Scientific Officer, Geneart .
- Dr Stefan Weinges, Manager, Scientific Sales Western Europe, Geneart Gmbh.
- 2.40 MEETING PROTEIN PRODUCTION DEMANDS THROUGHOUT THE BIOPHARMACEUTICAL DEVELOPMENT PROCESS
- Adapting production to variations in purification and scale
- Exploring the technical requirements for production aiding the stages of pre-clinical compound development
- Structuring the technological platforms to support proteins needed for every stage
- Dr Zhijian Lu, Assistant Director, Biotherapeutics Expression and Purification, Wyeth .
- 3.20 Afternoon Tea
- 3.40 CHARACTERIZATION AND QUANTITATION OF THERAPEUTIC MONOCLONAL ANTIBODIES USING LABCHIP SDS ELECTROPHORESIS
- High throughput, reliable, and reproducible method
- Labchip SDS Electrophoresis vs. CE-SDS results from Amgen study
- Rapid determination of molecular mass, quantity, and % purity
- Resolving between heavy chain and nonglycosylated heavy chain species present at low level
- Dr Bahram Fathollahi, Associate Director, Microfluidics Group, Caliper Life Sciences.
- 4.20 NI-NTA / TAGZYME TECHNOLOGIES: A CASE STUDY ON LARGE-SCALE PROTEIN MANUFACTURING AND CRYSTALLIZATION
- A Screening Tool for Solubility
- Presenting a fast and convenient approach to screen a large number of expression constructs
- Designing a manufacturing process that combines robust and well-documented technological platforms
- The TAGZyme™ system allows the efficient and precise exoproteolytic removal of N-terminal tags from recombinant proteins
- Provides high-purity proteins free of vector-encoded amino acids for use in applications that demand recombinant reagents, an absence of non-specific cleavage, and a complete removal of all impurities from the target-protein preparation
- Dr Frank Schaefer, Associate Director, Research and Development, QIAGEN.
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day Two
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Hans de Haard, Senior Director, Technology and Discovery, Ablynx.
- 9.10 OPTIMIZING PROTEIN THERAPEUTICS AS SUCCESSFUL CLINICAL CANDIDATES
- The critical role of Protein engineering
- Discovery strategies for therapeutic proteins and antibodies for various therapeutic arenas
- Review of design principles for simultaneously optimizing pharmacological efficacy and biochemical properties through protein engineering, along with preclinical and clinical examples
- The role of deimmunization engineering
- Dr Thomas F Bumol, Vice President, Biotechnology Discovery Research and Applied Molecular Evolution, Eli Lilly.
- 9.50 PRE-FORMULATION RESEARCH AND DEVELOPMENT OF THERAPEUTIC PROTEINS
- Strategies to characterize the solution behavior of proteins with limited amounts of material
- Biophysical and thermodynamic approaches in formulation development
- Optimizing discovery research, pre-formulation and formulation development interfaces
- Dr Bernardo Perez-Ramirez, Scientific Director, Bio-Formulations Development, Genzyme .
- 10.30 Morning Coffee
- 11.00 HIGH THROUGHPUT TECHNOLOGY OF EXPRESSED PROTEIN FOR STRUCTURAL ANALYSIS
- Shifting away from bacterial systems
- Richard Bazin, Scientist, Pfizer.
- 11.40 HIGH LEVEL PROTEIN PRODUCTION IN MAMMALIAN CELLS BY TRANSIENT TRANSFECTION
- Designing a protocol for production scale-up
- Transient transfection of CHO and 293 cells in suspension cultures
- Functional proteins (up to milligram quantities) with all post-translational modifications produced in one week
- Simplified downstream purification of secreted proteins with FreeStyle™ serum-free medium
- Dr Brian Dalby, Research and Development, Invitrogen.
- Dr Federico Katzen, Research and Development, Invitrogen.
- 12.20 GENOME-WIDE PROTEIN EXPRESSION SCREENING USING OMICSLINK™ HUMAN ORF EXPRESSION CLONES AND WHEAT GERM EXTRACT RTS™ CELL FREE
- Results of a large scale collaborative project for expression screening of more than 12,000 human full length protein coding ORF clones that has been completed jointly by GeneCopoeia and Roche
- The advantages of specially constructed OmicsLink™ human ORF expression clones and wheat germ extract RTS™ cell free system
- Features of the protein expression database system
- Applications of the cell free expression system, expression ready ORF clones, and recombinant proteins produced
- Dr Sun Lu, Executive Vice President, GeneCopoeia Inc.
- 1.00 Networking Lunch
- 1.50 NEW PERSPECTIVES FOR THE DIRECTED EVOLUTION OF THERAPEUTICAL PROTEINS
- Combining expression, ligase-based gene shuffling and immunogenicity assessment for enhanced performances
- Rapid cell-free and cell-based expression
- Evosight & L-Shuffling, leading-edge technologies for protein evolution
- New in-vitro assays for immunogenicity assessment
- Emmanuel Maille, General Manager, Business Development , Proteus S A.
- 2.30 CHALLENGES IN SCALE-UP OF A HETERODIMERIC CYTOKINE IL-23
- Cloning strategy
- Expression screening and scale-up
- Purification and characterization
- Dr Ramkrishna Sadhukhan, Senior Research Scientist, Bioresearch Centre, Abbott Laboratories.
- 3.10 Afternoon Tea
- 3.40 APPLICATION OF MICROFLUIDIC SAMPLE ANALYSIS IN HIGH-THROUGHPUT PROTEIN EXPRESSION
- Defining Protein-Protein Interaction Domains
- High-Throughput protein production allowed us to define the domains necessary for protein-protein interactions
- Caliper Labchip allowed for rapid analysis of both DNA and protein samples
- Widely divergent sizes could all be run together in a single analysis
- High accuracy and reproducibility allowed for confidence in sample identification
- Protein concentrations were within two-fold of manual Bradford values
- Dr William Clay Brown, Scientific Director, High-Throughput Protein Lab, Life Sciences Institute, University Of Michigan.
- 4.20 SMALLER SIZED ANTIBODIES AS NEW THERAPEUTIC ENTITIES
- Revisiting validated targets
- Antibody-derived therapeutic proteins based on naturally occurring heavy-chain antibodies derived from camelids
- Combining the pharmaceutical advantage of an antibody with advantageous traits of small molecule compound
- Added value brought to validated targets: the TNF-a case study
- Dr Hans de Haard, Senior Director, Technology and Discovery, Ablynx.
- 5.00 PSEUDOMONAS FLUORESCENS-BASED EXPRESSION TECHNOLOGY FOR THE
- High throughput methods for host strain and expression strategy selection
- The Pseudomonas-based Pfenex system is proven for high titer protein pharmaceutical production
- Off the shelf expression plasmids and proven host strains
- Effective high throughput methods to identify hosts producing high levels of active target protein
- Dr Charles H Squires, Senior Director, Biopharmaceutical Services, Dowpharma.
- 5.40 Chairman’s Closing Remarks and Close of Day Two
AbstractWith staggering growth rates, the booming Biopharmaceutical industry has been increasingly diverting resources to protein research.
Great contributions have been made through academic research but it is the pharmaceutical industry that solely faces unique challenges, in its strive to progress compounds into novel drugs:
- Targeting Expression and purification demands
- Optimizing Efficacy and activity levels
- Meeting demands for production scale up
- Overcoming challenges in structural research for drug design
The SMi Group’s 3rd Annual Global Protein Summit is designed to meet the needs of the industry.
Bringing together Vice Presidents, Directors, Heads and leading Researchers from the pharmaceutical industry to share successes and discuss the critical issues surrounding the development of innovative protein drug compounds. Hear contributions from leading industry experts, including:
- Dr Niels C Kaarsholm, Corporate Vice President, Protein Engineering, Diabetes Research, Novo Nordisk
- Dr Thomas Bumol, Vice President, Biotechnology Discovery Research and Applied Molecular Evolution, Eli Lilly
- Dr Robert Wynands, Director, Structural Biology, Takeda
- Dr Zhijian Lu, Assistant Director, Biotherapeutics Expression and Purification, Wyeth
- Dr Niek Dekker, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca
- Dr Cory R Brouwer, Associate Director, Knowledge Management Informatics, Pfizer
- Dr Bernardo Perez-Ramirez, Scientific Director, Bio-Formulations Development, Genzyme
- Dr Hans De Haard, Senior Director, Technology and Discovery, Ablynx
- Dr Charles H Squires, Senior Director, Biopharmaceutical Services, Dowpharma
- Dr Joey M Studts, Principal Scientist and Head, Protein Resources, Boehringer-Ingelheim
- Dr Stephen Irving, Senior Principal Scientist, Pfizer
- Dr Lukas Leder, Research Investigator, Protein Expression and Purification, Centre of Proteomic Chemistry, Novartis
- Dr Ramkrishna Sadhukhan, Bioresearch Centre, Abbott Laboratories
The SMi Group’s 3rd Annual Global Protein Summit offers a unique opportunity to hear about the latest developments from industry leaders. Bringing together knowledge and expertise, it’s designed to create the perfect setting for the exchange of ideas and networking opportunities.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
